Most Read Articles
13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.

Exploring the potential of targeted therapy for haematological malignancies

13 Feb 2020
The development of imatinib, a tyrosine kinase inhibitor (TKI), has revolutionised the treatment landscape of chronic myeloid leukaemia (CML); the 10-year survival rate of patients who received imatinib was 83.3%.1,2 Current ELN guidelines recommend either imatinib, nilotinib or dasatinib as first-line treatment for patients with CML.3 Owing to the development of resistance, lack of response or intolerance to imatinib, a proportion of patients initially treated with imatinib will require an alternative therapy.4,5 Moreover, while achieving an early molecular response (EMR; ie, BCR-ABL1IS ≤10% at 3 months) with TKI has been associated with a higher probability of achieving deep molecular response (DMR), the rate of EMR failure is higher with imatinib than nilotinib – a second-generation TKI.6,7
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.